This thesis reports on studies validating a modification of 'minimal' model analysis of the FSIVGTT to measure insulin resistance specifically in NIDDM subjects and its use along with a mixed meal test incorporating measurement of specific insulin and proinsulin concentrations to quantify changes in beta-cell function and insulin resistance following two years of diet or sulphonylurea treatment in established NIDDM. All NIDDM subjects displayed severe beta-cell dysfunction (post-prandial insulinopenia and hyperproinsulinaemia) and insulin resistance when compared to age and sex matched normals. Therapeutic interventions failed to normalise either of these abnormalities. Dietary therapy resulted in improved glycaemic control, weight loss and...
OBJECTIVE - We Studied the effects of the oral insulin secretagogue nateghnide on insulin secretion ...
We propose that combined therapy with insulin plus sulfonylurea can be a useful approach for the tre...
OBJECTIVE: Amylin, a secretory peptide of beta-cells, is the constituent peptide of islet amyloid, w...
This thesis reports on studies validating a modification of 'minimal' model analysis of the FSIVGTT ...
SECONDARY DRUG FAILURE IN NON INSULIN DEPENDENT DIABETESON CAUSES AND ASPECTS OF TREATMENTPer Claus...
Subjects with NIDDM have increased plasma proinsulin concentrations, compared with nondiabetic subje...
Sulphonylureas are an accepted and widely used treatment for hyperglycaemia in type 2 diabetes. The ...
Type 2 diabetes is a chronic disease characterized by progressive worsening of glycaemic control as ...
In order to identify early abnormalities in non-insulin-dependent diabetes mellitus (NIDDM) we deter...
AIM: We investigated the clinical and metabolic parameters in type 2 diabetic patients who were inad...
NIDDM is the result of concomitant defects in both insulin secretion and insulin action. Although pl...
Approximately 20-30% of patients with non-insulin-dependent diabetes mellitus (NIDDM) started on sul...
BackgroundThere were a limited number of studies about β-cell function after insulin initiation in p...
OBJECTIVE: To evaluate the efficacy of the addition of insulin when maximal sulfonylurea therapy is ...
Type 2 diabetes is a prevalent disorder characterized by elevated blood glucose levels and associate...
OBJECTIVE - We Studied the effects of the oral insulin secretagogue nateghnide on insulin secretion ...
We propose that combined therapy with insulin plus sulfonylurea can be a useful approach for the tre...
OBJECTIVE: Amylin, a secretory peptide of beta-cells, is the constituent peptide of islet amyloid, w...
This thesis reports on studies validating a modification of 'minimal' model analysis of the FSIVGTT ...
SECONDARY DRUG FAILURE IN NON INSULIN DEPENDENT DIABETESON CAUSES AND ASPECTS OF TREATMENTPer Claus...
Subjects with NIDDM have increased plasma proinsulin concentrations, compared with nondiabetic subje...
Sulphonylureas are an accepted and widely used treatment for hyperglycaemia in type 2 diabetes. The ...
Type 2 diabetes is a chronic disease characterized by progressive worsening of glycaemic control as ...
In order to identify early abnormalities in non-insulin-dependent diabetes mellitus (NIDDM) we deter...
AIM: We investigated the clinical and metabolic parameters in type 2 diabetic patients who were inad...
NIDDM is the result of concomitant defects in both insulin secretion and insulin action. Although pl...
Approximately 20-30% of patients with non-insulin-dependent diabetes mellitus (NIDDM) started on sul...
BackgroundThere were a limited number of studies about β-cell function after insulin initiation in p...
OBJECTIVE: To evaluate the efficacy of the addition of insulin when maximal sulfonylurea therapy is ...
Type 2 diabetes is a prevalent disorder characterized by elevated blood glucose levels and associate...
OBJECTIVE - We Studied the effects of the oral insulin secretagogue nateghnide on insulin secretion ...
We propose that combined therapy with insulin plus sulfonylurea can be a useful approach for the tre...
OBJECTIVE: Amylin, a secretory peptide of beta-cells, is the constituent peptide of islet amyloid, w...